The FDA's alignment on an accelerated approval pathway for AMT-130 is a transformative catalyst that likely overrides the headline earnings miss. Traders should focus on the BLA submission timeline and the four-year data readout in September 2026 as the next key catalysts. The $259M capital raise removes near-term financing risk and funds the commercial launch, but adds dilution.
Drugs in focus
QURE drug pipeline →AMT-130
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 1/2 (pivotal for accelerated approval)
- Time to market
- BLA submission planned for Q3 2026; FDA accelerated approval decision likely 6-10 months after submission (potentially H1 2027)
- Next catalyst
- None dated
What to watchThe BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 29 $40.07entry
- T+1 · 4mo ago +5.29%α +3.61% · $42.19
- T+5 · 3mo ago +10.41%α +4.88% · $44.24
- T+20 · 3mo ago +27.15%α +22.13% · $50.95
- T+60 · 26d ago −42.33%α −47.06% · $23.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
uniQure reported Q2 2026 results with a net loss of $1.22 per share, significantly missing the $-0.71 consensus estimate, while revenue of $5.8M slightly beat the $4.7M estimate. The headline miss is overshadowed by a transformative regulatory milestone: FDA alignment on an accelerated approval pathway for AMT-130 in Huntington's disease, with a BLA submission on track for Q3 2026. The company also strengthened its balance sheet with a $259M follow-on offering, extending the cash runway into 2030 and funding a potential commercial launch.
Key Financial Metrics
Key Facts
- FDA and uniQure reached alignment that a BLA submission under the accelerated approval pathway for AMT-130 is reasonable.
- BLA submission for AMT-130 on track for Q3 2026; topline four-year data expected in September 2026.
- Closed an upsized underwritten public offering of 5,686,813 shares at $45.50 per share for aggregate gross proceeds of $259 million.
- Cash, cash equivalents and current investment securities of $810.3 million as of June 30, 2026, sufficient to fund operations into 2030.
- Net loss of $81.1 million ($1.22 per share) for Q2 2026, compared to a net loss of $37.7 million ($0.69 per share) in Q2 2025.
- Revenue for Q2 2026 was $5.8 million, up from $5.3 million in Q2 2025.
Financial Impact
EPS miss of -72.4% vs consensus ($-1.22 actual vs $-0.71 estimate). Revenue beat of +23.4% vs consensus ($5.8M actual vs $4.7M estimate). Net loss widened to $81.1M from $37.7M YoY, driven by $27.0M in non-operating expenses (FX and warrant revaluation).
Risk Factors
- FDA may ultimately conclude that Phase I/II data are insufficient to support a BLA or accelerated approval.
- Confirmatory study design and enrollment timeline remain to be finalized with the FDA.
- Net loss widened significantly YoY due to non-operating items; operating expenses continue to rise.
- Dilution from the 5.7M share follow-on offering at $45.50 per share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-087808 |
| Document: qure-20260729x8k.htm | 0001104659-26-087808 |
| Document: 0001104659-26-087808-index-headers.html | 0001104659-26-087808 |
| Document: 0001104659-26-087808-index.html | 0001104659-26-087808 |
| Document: 0001104659-26-087808.txt | 0001104659-26-087808 |
| 8-K Data (Synthetic) | 0001104659-26-087808 |
Track record
38 reports on QURE
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +17.34% at T+20 after the Jun 23, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Viewing Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers